CN1152886C - 表现出溶解速度加快的依匹乐酮晶形 - Google Patents

表现出溶解速度加快的依匹乐酮晶形 Download PDF

Info

Publication number
CN1152886C
CN1152886C CNB008057788A CN00805778A CN1152886C CN 1152886 C CN1152886 C CN 1152886C CN B008057788 A CNB008057788 A CN B008057788A CN 00805778 A CN00805778 A CN 00805778A CN 1152886 C CN1152886 C CN 1152886C
Authority
CN
China
Prior art keywords
eplerenone
compound
medicine
solvent
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008057788A
Other languages
English (en)
Chinese (zh)
Other versions
CN1377365A (zh
Inventor
K
K·巴顿
T·B·波尔查德特
M·V·卡洛斯
S·德赛
L·J·菲罗
H·T·戈德
S·甘泽
C·R·利特勒
˹��������ͼ˹�����µ�
P·S·穆迪帕利
�����Ƥ��
M·A·皮茨
D·R·皮利保斯卡斯
L
Y·-L·L·邢
G·L·斯塔尔
ά
J·J·维佐雷克
C·Y·彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of CN1377365A publication Critical patent/CN1377365A/zh
Application granted granted Critical
Publication of CN1152886C publication Critical patent/CN1152886C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CNB008057788A 1999-12-08 2000-12-04 表现出溶解速度加快的依匹乐酮晶形 Expired - Fee Related CN1152886C (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US16968299P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16969099P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US60/169608 1999-12-08
US60/169682 1999-12-08
US60/169807 1999-12-08
US60/169556 1999-12-08
US60/169639 1999-12-08
US60/169690 1999-12-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100368081A Division CN1557833A (zh) 1999-12-08 2000-12-04 表现出溶解速度加快的依匹乐酮晶形

Publications (2)

Publication Number Publication Date
CN1377365A CN1377365A (zh) 2002-10-30
CN1152886C true CN1152886C (zh) 2004-06-09

Family

ID=27558585

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB008057788A Expired - Fee Related CN1152886C (zh) 1999-12-08 2000-12-04 表现出溶解速度加快的依匹乐酮晶形
CNA2004100368081A Pending CN1557833A (zh) 1999-12-08 2000-12-04 表现出溶解速度加快的依匹乐酮晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100368081A Pending CN1557833A (zh) 1999-12-08 2000-12-04 表现出溶解速度加快的依匹乐酮晶形

Country Status (17)

Country Link
EP (1) EP1177204A2 (https=)
JP (1) JP2003516414A (https=)
KR (1) KR100607923B1 (https=)
CN (2) CN1152886C (https=)
AU (1) AU784946B2 (https=)
BR (1) BR0008057A (https=)
CA (1) CA2362669A1 (https=)
CO (1) CO5280211A1 (https=)
EA (1) EA007934B1 (https=)
HU (1) HUP0203032A3 (https=)
IL (3) IL144764A0 (https=)
MX (1) MXPA01008056A (https=)
MY (1) MY131878A (https=)
NO (1) NO20013856L (https=)
NZ (2) NZ513961A (https=)
PE (1) PE20010917A1 (https=)
WO (1) WO2001042272A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487540A2 (en) * 2002-03-20 2004-12-22 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
EP2977084B1 (en) 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции
CN120754115A (zh) * 2025-05-23 2025-10-10 远大医药（中国）有限公司 一种含依普利酮组合物及其药物制剂、制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
WO1998025948A2 (en) * 1996-12-11 1998-06-18 G.D. Searle & Co. Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
DE60005159T2 (de) * 1999-03-05 2004-07-22 G.D. Searle Llc, Chicago Kombinationstherapie von angiotensin-konvertierendem enzym hemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen

Also Published As

Publication number Publication date
HUP0203032A2 (hu) 2002-12-28
EA007934B1 (ru) 2007-02-27
CN1557833A (zh) 2004-12-29
CN1377365A (zh) 2002-10-30
MXPA01008056A (es) 2003-07-21
EP1177204A2 (en) 2002-02-06
AU784946B2 (en) 2006-08-03
HUP0203032A3 (en) 2003-04-28
PE20010917A1 (es) 2001-09-10
MY131878A (en) 2007-09-28
NZ513961A (en) 2004-02-27
EA200100871A1 (ru) 2002-04-25
NO20013856L (no) 2001-10-08
WO2001042272A2 (en) 2001-06-14
WO2001042272A3 (en) 2001-11-29
WO2001042272A9 (en) 2002-12-12
CO5280211A1 (es) 2003-05-30
NO20013856D0 (no) 2001-08-08
IL144764A (en) 2007-08-19
BR0008057A (pt) 2002-04-23
NZ530028A (en) 2005-08-26
IL144764A0 (en) 2002-06-30
IL176511A (en) 2007-08-19
KR100607923B1 (ko) 2006-08-04
JP2003516414A (ja) 2003-05-13
CA2362669A1 (en) 2001-06-14
KR20010112261A (ko) 2001-12-20
AU2049201A (en) 2001-06-18
HK1050536A1 (en) 2003-06-27

Similar Documents

Publication Publication Date Title
CN1152886C (zh) 表现出溶解速度加快的依匹乐酮晶形
CN1146567C (zh) 奥氮平二水合物d
CN1273466C (zh) 具有唑基的喹啉衍生物和喹唑啉衍生物
CN1204143C (zh) EtO2C－CH2－(R)Cgl－Aze－Pab－OH的晶形
CN1085223A (zh) 17-β-取代的-4-氮杂-5α-雄烷-3-酮衍生物
CN1516699A (zh) 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的多晶型物
CN1589256A (zh) 盐酸舍曲林的新多晶型物和含有它们的组合物,制备盐酸舍曲林多晶型物和无定形物的新方法
CN1433427A (zh) 依匹乐酮晶型
CN1269823C (zh) 作为抗心律不齐化合物的3,7－二氮杂双环[3.3.1]制剂
CN101052631A (zh) 结晶霉酚酸钠
CN101076538A (zh) 用于癌症治疗的类固醇
CN1655760A (zh) 速释药物制剂
CN1095383A (zh) 取代的6-氮杂雄甾烯酮
CN101068916A (zh) 阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途
CN1665504A (zh) 新晶型的加替沙星
CN1145617A (zh) 吲哚衍生物及含它们的药物
CN1152687C (zh) 三甲曲沙盐结晶及其制备方法
CN1158299C (zh) 取代的4-苄基氨基喹啉、其制备方法、含有这些化合物的药物及其应用
CN1272842A (zh) 作为速激肽受体拮抗剂的2－酰氨基丙胺类化合物
CN1177350A (zh) 咪唑衍生物及其药学组合物
HK1050536B (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
CN1102529A (zh) 氟化4-氨基雄甾二烯酮衍生物及其制备方法
CN1178651C (zh) 冷冻干燥的噻吨酮抗肿瘤剂
CN1891209A (zh) 表现出溶解速度加快的依匹乐酮晶形
CN1791406A (zh) 5－(二氟甲氧基)－2－[[(3,4－二甲氧基－2－吡啶基)甲基]亚硫酰基]－1h－苯并咪唑(泮托拉唑)钠水络合物的固态形式

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1050536

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040609

Termination date: 20111204